IMDX
Insight Molecular Diagnostics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.13
+0.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7M | 4.1M | 1.9M | 1.5M | 958.0K |
| Cost of Revenue | 1.5M | 3.9M | 1.1M | 1.1M | 976.0K |
| Gross Profit | 186.5K | 190.0K | 740.0K | 413.0K | (18.0K) |
| Operating Expenses | |||||
| R&D Expense | 18.8M | 15.9M | 9.8M | 9.3M | 7.3M |
| SG&A Expense | 18.5M | 17.0M | 13.8M | 13.3M | 21.5M |
| General & Admin Expense | 12.4M | 10.6M | 13.1M | 13.0M | 21.5M |
| Selling & Marketing Expense | 6.1M | 6.3M | 641.0K | 307.0K | 17.0K |
| Other Expenses | 5.6M | (2.1M) | 38.2M | 3.0M | (10.9M) |
| Total Operating Expenses | 42.9M | 30.8M | 61.8M | 25.5M | 18.0M |
| Cost and Expenses | 44.4M | 34.6M | 62.9M | 26.6M | 19.0M |
| Operating Income (EBIT) | (42.7M) | (30.6M) | (61.0M) | (25.1M) | (18.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 98.0K | 109.0K | 84.0K | 52.0K | 83.0K |
| Net Interest Income | (98.0K) | (109.0K) | (84.0K) | (52.0K) | (83.0K) |
| Other Non-Op Income/Expense | (6.6M) | (19.6M) | 378.0K | 281.0K | (615.0K) |
| Non-Operating Income (excl Interest) | 6.5M | 19.5M | (462.0K) | (333.0K) | 532.0K |
| EBT (Pre-Tax Income) | (49.4M) | (50.2M) | (60.7M) | (24.9M) | (18.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (49.4M) | (50.2M) | (60.7M) | (27.8M) | (72.9M) |
| Earnings from Cont. Ops | (49.4M) | (50.2M) | (60.7M) | (24.9M) | (18.6M) |
| Earnings from Discont. Ops | — | — | — | (2.9M) | (54.3M) |
| Bottom Line Net Income | (49.4M) | (50.2M) | (60.9M) | (28.7M) | (73.4M) |
| Per Share | |||||
| Basic EPS | ($1.52) | ($1.65) | ($4.66) | ($3.75) | ($20.00) |
| Diluted EPS | ($1.52) | ($1.65) | ($4.66) | ($3.75) | ($20.00) |
| Revenue Per Share | $0.05 | $0.13 | $0.14 | $0.20 | $0.17 |
| Shares | |||||
| Basic Shares Outstanding | 36.8M | 30.5M | 13.1M | 7.7M | 5.5M |
| Diluted Shares Outstanding | 36.8M | 30.5M | 13.1M | 7.7M | 5.5M |
| Profitability Metrics | |||||
| EBITDA | (46.8M) | (47.9M) | (59.0M) | (23.1M) | (13.3M) |
| D&A | 2.4M | 2.2M | 1.6M | 1.7M | 5.2M |
| EBIT | (49.3M) | (50.1M) | (60.6M) | (24.8M) | (18.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026